A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women
Latest Information Update: 11 Nov 2022
Price :
$35 *
At a glance
- Drugs Dapivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms DREAM
- 08 Nov 2022 Results of an analysis from two clinical studies: DREAM and Ring-study assessing population-based genotyping performed on plasma samples collected longitudinally and next generation sequencing and phenotypic susceptibility testing done on plasma collected at seroconversion published in the Clinical Infectious Diseases
- 03 Oct 2022 Results (n=150) of post hoc virology analysis assessing Clinical Presentation, Treatment Response and Virology Outcomes of Women who Seroconverted in the Dapivirine Vaginal Ring Trials published in the Clinical Infectious Diseases
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.